What is Brief History of Pharvaris Company?

What is the history of Pharvaris?

Pharvaris, a clinical-stage biopharmaceutical company, has emerged as a significant player in the rare disease space, particularly in addressing hereditary angioedema (HAE).

Founded in 2015, Pharvaris N.V. established its headquarters in Leiden, the Netherlands, with a vision to bring oral bradykinin B2-receptor antagonists to patients with rare diseases.

The company's core focus is on HAE, a rare genetic disorder, and other bradykinin-mediated diseases. As of July 2025, Pharvaris maintains a strong market position, evidenced by its ongoing pivotal Phase 3 studies for deucrictibant, its lead candidate, for both on-demand and prophylactic HAE treatment. The company's current market capitalization stands at approximately $1.32 billion as of July 25, 2025.

Pharvaris N.V. officially began its journey on September 30, 2015, in Leiden, the Netherlands. The company was established by a team possessing substantial experience in the rare disease sector, driven by a mission to address a significant unmet medical need.

The Genesis of Pharvaris

Pharvaris company was founded by a group of experts deeply familiar with rare diseases, including Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage. Berndt Modig also took on the role of Co-Founder and CEO, steering the company’s initial direction.

• The founders recognized a critical need for convenient, oral treatment options for hereditary angioedema (HAE).
• Existing HAE treatments often involved injectables and infusions, necessitating frequent hospital visits.
• The company's initial focus was on developing novel, oral bradykinin B2 receptor antagonists.
• Deucrictibant, also known as PHVS416 and PHVS719, was identified as their first product candidate.

The core of Pharvaris's original business model revolved around the development of innovative, oral bradykinin B2 receptor antagonists. Deucrictibant, identified by the company as PHVS416 and later PHVS719, was the lead product candidate. This small molecule was engineered to block the bradykinin B2 receptor, thereby preventing the excessive fluid leakage from blood vessels into surrounding tissues characteristic of HAE attacks. While specific initial funding details are not publicly available, the company's early trajectory clearly indicated a strong emphasis on advancing its research into the clinical stages. The collective expertise of the founding team in rare diseases, particularly HAE, was a foundational element in shaping the company’s strategic direction and its commitment to offering oral alternatives that could significantly improve the standard of care for patients. Understanding the intricacies of patient needs, as detailed in the Marketing Strategy of Pharvaris, was central to this vision.

Since its founding in 2015, the company has systematically advanced its lead candidate, deucrictibant, through various clinical stages. By March 31, 2023, the company held €135 million in cash and cash equivalents, supporting its ongoing studies and early growth, marked by positive Phase 2 data in HAE.

Early Clinical Development and Financial Strength

Following its 2015 founding, the company focused on preclinical and early-phase clinical development for deucrictibant. By March 31, 2023, the company reported €135 million in cash and cash equivalents, bolstering its capacity for continued research and development, including pivotal studies.

Milestone Data and Pivotal Trials Initiation

Positive Phase 2 data from prophylaxis and on-demand studies in HAE marked a significant early milestone. In 2024, the company initiated CHAPTER-3, a pivotal Phase 3 study for deucrictibant as a prophylactic treatment, with topline data expected in the second half of 2026.

Expansion into Acquired Angioedema and Market Strategy

The company is expanding its pipeline to include acquired angioedema (AAE) due to C1-INH deficiency, with a clinical study planned for 2025. This move into an underserved niche positions the company for potential first-mover advantage, aiming to capture a significant share of the U.S. HAE prophylaxis segment.

Pipeline Progression and Market Entry Preparations

Enrollment continues for RAPIDe-3, a pivotal Phase 3 study for on-demand HAE treatment, with topline data anticipated in early 2026, potentially Q4 2025. Recent key hires in Sales & Marketing and Business Development signal preparations for market entry, building on the Revenue Streams & Business Model of Pharvaris.

The Pharvaris company history is a narrative of focused development in rare diseases, marked by significant clinical progress and strategic financial maneuvers. This Brief History of Pharvaris outlines the key stages of its journey.

Deucrictibant: Oral Bradykinin B2 Receptor Antagonist

A core innovation is deucrictibant, a novel, oral bradykinin B2 receptor antagonist. This therapy is being developed in two forms: an immediate-release capsule for on-demand treatment and an extended-release tablet for prophylactic use in HAE.

Addressing Unmet Needs in HAE Treatment

The development of an oral treatment aims to provide a more convenient alternative to existing injectable and infusion therapies for Hereditary Angioedema (HAE). This focus addresses a significant unmet need in patient care.

Orphan Drug Designations

Deucrictibant has received orphan drug designation from the U.S. Food and Drug Administration and orphan designation by the European Commission. These designations underscore the potential of deucrictibant in treating rare diseases.

The company has navigated significant financial challenges to support its late-stage clinical programs and U.S. market entry. These challenges are inherent in biopharmaceutical development, requiring substantial capital investment.

Capital Raising for Clinical Programs

Funding late-stage clinical trials and preparing for market entry necessitates significant capital. The company has actively pursued financing to support these critical development phases.

Public Offering Success

In July 2025, an upsized public offering successfully raised $201.2 million. This capital infusion is crucial for advancing the company's pipeline and extending its cash runway into Q3 2026.

Managing Share Dilution

While public offerings can lead to share dilution, the strategic necessity of securing funds for development is paramount. The company's ability to raise capital demonstrates confidence in its future prospects.

The Pharvaris company timeline highlights its swift journey from its inception to becoming a late-stage biopharmaceutical entity. The company's origins trace back to its incorporation in the Netherlands, marking the beginning of its focused development in rare diseases.

Deucrictibant Development Milestones

The company's focus remains on advancing deucrictibant through critical clinical trials. Key upcoming data readouts are expected in late 2025 and mid-2026, pivotal for regulatory submissions.

Financial Strength and Runway

With a cash runway extending into Q3 2026, Pharvaris is well-positioned to fund its ongoing development and commercialization efforts. This financial stability supports its strategic objectives.

Market Opportunity and Strategy

The HAE market is projected for significant growth, with Pharvaris aiming for a substantial market share in the U.S. prophylaxis segment. The company's strategy centers on providing convenient oral therapies.

Future Vision and Impact

Pharvaris' long-term vision is to become a leader in oral therapies for bradykinin-mediated angioedema. This aligns with its founding mission to enhance the quality of life for patients with rare conditions, building on its Competitors Landscape of Pharvaris.